Synergistic activities between carbapenems and other antimicrobial agents against Acinetobacter baumannii including multidrug-resistant and extensively drug-resistant isolates.
Treatment options for multidrug-resistant (MDR) and extensively drug-resistant (XDR) Acinetobacter baumannii have been seriously limited and may require combination antimicrobial therapy. In this study, we searched for synergistic activity between carbapenems (doripenem, imipenem and meropenem) and various non-traditional agents (cefoperazone/sulbactam, doxycycline, rifampicin, netilmicin and moxifloxacin) against 40 A. baumannii clinical isolates, including MDR and XDR isolates. The results showed that combination of each carbapenem with cefoperazone/sulbactam, based on the Etest method, demonstrated synergy more frequently (17.5-32.5%) than the other tested agents, which may suggest a role in combination therapy against highly resistant A. baumannii.
Kiratisin
Pattarachai
P
Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Prannok Road, Bangkok-Noi, Bangkok 10700, Thailand. sipkr@mahidol.ac.th
Apisarnthanarak
Anucha
A
Kaewdaeng
Srirumpa
S
D000151:Acinetobacter Infections / Q000382:microbiology; D040981:Acinetobacter baumannii / Q000187:drug effects* / Q000302:isolation & purification; D000890:Anti-Infective Agents / Q000494:pharmacology*; D015780:Carbapenems / Q000494:pharmacology*; D024901:Drug Resistance, Multiple, Bacterial; D004357:Drug Synergism; D006801:Humans; D008826:Microbial Sensitivity Tests
D000890:Anti-Infective Agents; D015780:Carbapenems